Zheng Quan Zhi Xing·2025-09-01 04:32Core Viewpoint - The report indicates that Tiankang Biological (002100) has shown steady revenue growth and improved profitability in H1 2025, with a buy rating recommended by China Galaxy Securities [1][2]. Financial Performance - In H1 2025, the company's revenue reached 8.847 billion yuan, a year-on-year increase of 10.68%, with net profit attributable to shareholders at 338 million yuan, up 22.27% year-on-year [2]. - For Q2 2025, revenue was 4.666 billion yuan, also reflecting a 10.68% year-on-year growth, but net profit decreased by 14.59% to 190 million yuan [2]. - The comprehensive gross margin for H1 2025 was 12.07%, an increase of 0.58 percentage points year-on-year, while the expense ratio decreased to 7.15% [2]. Business Segments - The revenue contributions from various segments in H1 2025 included pig farming (2.849 billion yuan, -0.95% YoY), feed (2.434 billion yuan, -14.24% YoY), agricultural product processing (1.449 billion yuan, +97.6% YoY), veterinary biological products (482 million yuan, -3.67% YoY), and corn silage (1.305 billion yuan, +72.32% YoY) [2][3]. - The company aims to achieve a pig output target of 3.5 to 4 million heads in 2025, representing a year-on-year increase of 15.57% to 32.08% [3]. Research and Development - In H1 2025, the company invested 113 million yuan in R&D, a decrease of 26.85% year-on-year, with new products expected to drive future growth in the vaccine business [4]. - The targets for animal vaccines and feed sales in 2025 are set at 2.4 billion milliliters and 2.9 million tons, respectively, indicating growth of 16.28% and 2.9% year-on-year [4]. Investment Outlook - The company is positioned as an integrated farming enterprise with stable growth in feed and veterinary medicine businesses, alongside a positive outlook for pig farming due to ongoing cost optimization [4]. - EPS forecasts for 2025 and 2026 are 0.54 yuan and 0.68 yuan, respectively, with corresponding PE ratios of 12 times and 10 times [4].